French court issues rare injunction, awards Novartis €13m
A French court has issued a preliminary injunction against Teva’s generic anti-hypertensive drug and awarded €13 million as an advance on damages
The Tribunal de Grande Instance of Paris delivered the injunction against Teva’s generic version of Exforge (valsartan/amlodipine), which has been patented by Novartis at the EPO (EP2322174).
The court ordered Teva to pay €5.8 million ($6.8 million) to...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.